Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Marginal Zone Lymphoma
Drug:
Aliqopa (copanlisib)
(
PIK3CA inhibitor
,
PI3Kδ inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Marginal Zone Lymphoma: Second-line and Subsequent Therapy...Other recommended regimens…PI3K inhibitors (relapsed/refractory after 2 prior therapies)…Copanlisib
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login